Abstract

BackgroundSubcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. A trained person can administer it, including women through self-injection. The objective of this systematic review and meta-analysis was to assess the effectiveness and safety of self-injection versus provider-administered subcutaneous depot medroxyprogesterone acetate for improving continuation of contraceptive use.MethodsWe searched for randomized controlled trials on November 1, 2020 in Cochrane Central Register of Controlled Trials, MEDLINE, CINAHL, Embase, Web of Science, Scopus, Open Grey, clinical trials registries, and reference lists of relevant studies. We did not impose any search restrictions. We included randomized trials comparing self- versus provider-administered subcutaneous depot medroxyprogesterone acetate. Two authors independently screened trials, extracted data, and assessed the risk of bias in the included studies. We used risk ratio and 95% confidence intervals for dichotomous outcomes.ResultsWe identified 3 randomized trials (9 reports; 1264 participants). The risk of bias in the included studies was low except for performance bias and detection bias of participant-reported outcomes in unmasked trials. Self-administration, compared to provider-administration, increased continuation of contraceptive use (risk ratio 1.35; 95% confidence intervals 1.10–1.66); moderate-certainty evidence). Self-injection appears to be making more of an impact on continuation for younger women compared to women 25 years and older and on women living in low and middle income compared to high income countries. There was no subgroup difference by the type of care provider (community health worker vs. clinic-based provider).ConclusionsSelf-injection of subcutaneous depot medroxyprogesterone acetate probably improves continuation of contraceptive use. The effects on other outcomes remain uncertain because of the very low certainty of evidence.

Highlights

  • Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive

  • Studies demonstrated that a single injection of Depo-Medroxyprogesterone Acetate (DMPA)-SC (104 mg medroxyprogesterone acetate/0.65 mL) provided immediate suppression of ovulation and consistently suppressed ovulation over 13 weeks, with the earliest return to ovulation at 15 weeks

  • We presented results as summary risk ratio (RR) with 95% confidence intervals (CI)

Read more

Summary

Introduction

Subcutaneous depot medroxyprogesterone acetate is an easy-to-use injectable contraceptive. The objective of this systematic review and meta-analysis was to assess the effectiveness and safety of self-injection versus provider-administered subcutaneous depot medroxyprogesterone acetate for improving continuation of contraceptive use. Most women who want a safe, effective, and reversible method can use DMPA injectable contraception [1]. Studies demonstrated that a single injection of DMPA-SC (104 mg medroxyprogesterone acetate/0.65 mL) provided immediate suppression of ovulation and consistently suppressed ovulation over 13 weeks, with the earliest return to ovulation at 15 weeks. This consistent suppression of ovulation with this 30% lower dose, was independent of body mass index or race. The subcutaneous route has been shown to have comparable efficacy and safety to the intramuscular route [3]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call